The full timeline: 10-15 years on average
FDA drug approval takes an average of 12 years from discovery to pharmacy shelves and costs $1-2 billion. Only 12% of drugs entering Phase I trials reach approval. The other 88% fail somewhere along the way, most often in Phase II when efficacy testing begins.
| Stage | Duration | Success Rate |
|---|---|---|
| Preclinical (lab/animal) | 3-6 years | ~1 in 5,000 compounds advance |
| Phase I (safety) | 1-2 years | 63% proceed to Phase II |
| Phase II (efficacy) | 2-3 years | 31% proceed to Phase III |
| Phase III (large trials) | 3-4 years | 58% proceed to NDA |
| FDA Review (NDA/BLA) | 6-12 months | 85% of submitted NDAs approved |
Preclinical: before human testing
Before any human receives a drug, the sponsor must demonstrate safety in laboratory and animal studies. This stage produces the pharmacokinetics (how the body processes the drug) and toxicology data that FDA requires before allowing clinical trials.
The sponsor files an Investigational New Drug (IND) application. The FDA has 30 days to review. If no clinical hold is issued, trials can begin.
Phase I: first-in-human safety
Phase I trials enroll 20-80 healthy volunteers (or patients for cancer drugs). The goals are narrow:
- Determine safe dosage range
- Identify side effects
- Understand absorption, distribution, metabolism, excretion (ADME)
These trials are not designed to test whether the drug works. They answer: "Is it safe enough to keep testing?"
Phase II: does it work?
Phase II trials enroll 100-300 patients with the target condition. These are typically randomized controlled trials comparing the drug to placebo or standard of care.
Goals:
- Demonstrate preliminary efficacy
- Refine dosing
- Identify common adverse reactions
- Establish endpoints for Phase III
This is where most drugs fail. The 31% success rate from Phase II to Phase III reflects how many compounds show activity in small trials but fail to demonstrate clinically meaningful benefit.
Phase III: large-scale confirmation
Phase III trials enroll 1,000-5,000+ patients across multiple sites. They generate the pivotal data that FDA uses for approval decisions.
Characteristics:
- Randomized, double-blind, placebo-controlled (usually)
- Multi-site (often international)
- Pre-specified primary endpoints
- Statistical analysis plans filed before unblinding
The sponsor typically runs two adequate and well-controlled Phase III trials. One positive trial is sometimes sufficient for rare diseases or breakthrough therapies.
NDA submission and FDA review
After successful Phase III trials, the sponsor submits a New Drug Application (NDA) for small molecules or a Biologics License Application (BLA) for biologics.
An NDA package contains:
- Full clinical trial data from all phases
- Chemistry, manufacturing, and controls (CMC)
- Proposed labeling
- Risk evaluation and mitigation strategy (REMS) if needed
FDA assigns a review division and a target action date:
- Standard review: 10 months
- Priority review: 6 months (for drugs offering significant improvement over existing treatments)
Expedited pathways
Four programs can accelerate the timeline:
| Program | Benefit | Criteria |
|---|---|---|
| Fast Track | More frequent FDA meetings, rolling review | Serious condition, unmet need |
| Breakthrough Therapy | All Fast Track benefits + intensive guidance | Preliminary evidence of substantial improvement |
| Accelerated Approval | Approval based on surrogate endpoint | Serious condition, meaningful advantage |
| Priority Review | 6 months instead of 10 | Significant improvement in safety/efficacy |
A drug can qualify for multiple programs simultaneously. Breakthrough therapy designation is the most impactful: drugs with this designation have a 70%+ approval rate.
Where to find approval data
Drugs@FDA (accessdata.fda.gov/scripts/cder/daf): Searchable database of all approved drugs with review documents, labeling, and approval letters.
openFDA drugsfda endpoint:
# Search for recent approvals
curl "https://api.fda.gov/drug/drugsfda.json?search=submissions.submission_type:\"ORIG\"+AND+submissions.submission_status_date:[20260101+TO+20261231]&limit=10"
FDA Orange Book: Lists approved drug products with therapeutic equivalence evaluations. Useful for identifying generic equivalents.
ClinicalTrials.gov: The trial registry tracks all phases. Each entry links to published results and FDA review documents when available.
2026 approval trends
Through the first seven months of 2026, the FDA's Center for Drug Evaluation and Research (CDER) has approved approximately 25 novel drugs. This pace is consistent with the 50-55 novel approvals per year seen in 2023-2025.
Notable trends:
- GLP-1 receptor agonists continue expanding indications (MASH, cardiovascular risk reduction)
- Gene therapy approvals accelerating (4 in first half of 2026)
- AI-designed molecules reaching approval for the first time
- Oncology remains the largest therapeutic area for new approvals
How long after Phase III does FDA approval take?
The gap between completing Phase III trials and receiving FDA approval is typically 12-18 months. Here's the breakdown:
| Step | Duration |
|---|---|
| Phase III data analysis and NDA preparation | 3-6 months |
| NDA submission and FDA filing decision | 2 months (60-day filing review) |
| FDA review period (standard) | 10 months from filing |
| FDA review period (priority) | 6 months from filing |
| Advisory committee meeting (if requested) | During review period |
| Complete Response Letter and resubmission (if issued) | Adds 6-12 months |
So from last patient enrolled in Phase III to approval: roughly 18-24 months for standard review, 12-16 months for priority review. If the FDA issues a Complete Response Letter (requesting additional data), add another 6-12 months.
Real example: Eli Lilly's tirzepatide (Mounjaro) completed its Phase III SURPASS trials in mid-2021, submitted the NDA in October 2021, and received approval in May 2022 — about 10 months from submission, 14 months from Phase III completion.
NDA vs. BLA: which pathway applies
New Drug Applications (NDA) and Biologics License Applications (BLA) follow similar review processes but apply to different drug types.
| NDA | BLA | |
|---|---|---|
| Drug type | Small molecules (chemicals) | Biologics (proteins, antibodies, gene/cell therapies) |
| Review center | CDER | CDER or CBER (depending on product) |
| Manufacturing requirements | Chemistry, Manufacturing, Controls (CMC) | More extensive: cell line characterization, process validation |
| Generic pathway | ANDA (Abbreviated NDA) | Biosimilar (351(k) application) |
| Data exclusivity | 5 years (NCE) | 12 years |
| Examples | Ozempic, Eliquis, metformin | Humira, Keytruda, insulin analogs |
The longer data exclusivity for biologics (12 years vs. 5) is why biosimilars take longer to reach market than traditional generics.
Rolling submissions: how they shorten the timeline
In a standard submission, the sponsor waits until the entire NDA package is complete, then submits everything at once. The FDA's clock starts when the full application arrives.
A rolling submission allows sponsors to send completed sections of the NDA as they finish, rather than waiting for the whole package. The FDA reviews each module as it arrives. By the time the final section lands, reviewers have already worked through most of the application.
Rolling submissions are available to drugs with Fast Track designation. The time savings: typically 2-4 months compared to standard submission.
Standard: [Prepare NDA ~6mo] → [Submit all] → [FDA review 10mo]
Rolling: [Submit Module 1] → [Submit M2] → [Submit M3] → [FDA review overlaps]
What happens on and after the PDUFA date
The PDUFA (Prescription Drug User Fee Act) date is the FDA's self-imposed deadline to complete their review. It is not a guaranteed approval date.
Three outcomes on or before the PDUFA date:
-
Approval letter. The drug is approved. The company can begin marketing immediately (if manufacturing and labeling are ready).
-
Complete Response Letter (CRL). The FDA requires additional information before approving. Common reasons: manufacturing facility deficiencies, requests for additional clinical data, labeling disagreements. A CRL resets the clock — the company resubmits, and a new 6-10 month review cycle begins.
-
Extension. The FDA can extend its review by 3 months if the sponsor submits a major amendment (new data, protocol changes) late in the review cycle.
About 85% of NDA submissions eventually receive approval. But only 60-70% are approved on the first PDUFA date — the rest require at least one resubmission after a CRL.
Advisory committee meetings
The FDA may (but is not required to) convene an Advisory Committee (AdComm) of external experts to review a drug before making its decision. AdComm meetings are public, streamed live, and produce a vote (typically "yes/no" on whether benefits outweigh risks).
When does FDA convene an AdComm?
- First-in-class drugs with novel mechanisms
- Drugs with borderline benefit-risk profiles
- Products that generated safety signals in trials
- Drugs for serious conditions where a prior application was rejected
The FDA follows the AdComm vote about 75% of the time. A favorable vote (12-3 in favor, for example) is not a guarantee of approval but makes it highly likely.
Timeline impact: AdComm meetings happen during the review period, so they don't add time. But a negative vote often leads to a CRL, which adds 6-12+ months.
Accelerated approval: faster to market, but with strings
Accelerated approval lets the FDA approve drugs based on a surrogate endpoint (a lab measurement reasonably likely to predict clinical benefit) rather than waiting for actual clinical outcomes.
Example: an oncology drug approved based on tumor shrinkage (surrogate) rather than overall survival (clinical endpoint). The drug reaches patients years earlier, but the sponsor must run post-market confirmatory trials to verify the surrogate actually predicts real benefit.
If confirmatory trials fail, the FDA can withdraw accelerated approval. This happened in 2022-2023 when several oncology drugs had their accelerated approvals revoked after confirmatory trials were negative.
Accelerated approval drugs since 2020: approximately 30% of novel drug approvals have used this pathway, predominantly in oncology and rare diseases.
Costs at each stage
The financial scale of drug development, based on industry averages:
| Stage | Typical Cost |
|---|---|
| Preclinical | $10-50M |
| Phase I | $20-50M |
| Phase II | $50-150M |
| Phase III | $150M-$500M+ |
| NDA preparation and PDUFA fee | $10-20M (fee alone: ~$4M in 2026) |
| Post-market requirements | $20-100M |
| Total (successful drug) | $500M-$2B+ |
These are costs for a single successful drug. Factor in the ~88% failure rate, and the total R&D cost per approved drug (including failed candidates) averages $1-2.6 billion, depending on whose estimate you use.
The PDUFA fee alone is approximately $4.0 million for a new NDA in 2026. Small companies and orphan drugs qualify for fee waivers.
Post-approval: what happens after FDA says yes
Approval is not the end of FDA oversight. Post-market requirements include:
Phase IV studies. The FDA can require additional studies after approval to monitor long-term safety, study use in populations excluded from trials (pregnant women, children), or confirm benefit in accelerated approval drugs.
REMS (Risk Evaluation and Mitigation Strategy). For drugs with serious safety concerns, the FDA may require special prescribing restrictions, patient monitoring, or distribution controls. Example: isotretinoin (Accutane) requires pregnancy testing and a prescribing registry.
Labeling supplements. As new safety data emerges post-market, sponsors submit labeling updates (new warnings, contraindications, drug interactions). The FDA reviews and approves these separately.
Manufacturing inspections. The FDA inspects manufacturing facilities before and after approval. Facility failures can result in warning letters, consent decrees, or even product withdrawals — unrelated to the drug's efficacy.
Where to find real-time approval data
Track drugs currently under FDA review and recently approved:
Drugs@FDA database (accessdata.fda.gov/scripts/cder/daf): Searchable database of all approved drugs with review documents, approval letters, and complete labeling history.
openFDA drugsfda endpoint:
# Search for recent approvals
curl "https://api.fda.gov/drug/drugsfda.json?search=submissions.submission_type:\"ORIG\"+AND+submissions.submission_status_date:[20260101+TO+20261231]&limit=10"
FDA Orange Book: Lists approved drug products with therapeutic equivalence evaluations. The primary source for identifying which generics are equivalent to which brands.
PDUFA date trackers: Several industry sources publish upcoming PDUFA dates (target FDA decision dates). These tell you when to expect the next big approval announcement.
ClinicalTrials.gov: Every clinical trial registers here. Check Phase III status to identify drugs 12-18 months from potential NDA submission.
2026 approval trends
Through the first seven months of 2026, the FDA's Center for Drug Evaluation and Research (CDER) has approved approximately 25 novel drugs. This pace is consistent with the 50-55 novel approvals per year seen in 2023-2025.
Notable trends:
- GLP-1 receptor agonists continue expanding indications (MASH, cardiovascular risk reduction, sleep apnea)
- Gene therapy approvals accelerating (4 in first half of 2026)
- AI-designed molecules reaching approval for the first time
- Oncology remains the largest therapeutic area for new approvals (~35%)
- Rare disease drugs represent about 40% of novel approvals (driven by orphan drug incentives)
FAQ
What is the difference between NDA and BLA? NDA covers small-molecule drugs (chemical compounds). BLA covers biologics (proteins, antibodies, gene therapies, vaccines). The review process is similar, but manufacturing requirements and data exclusivity periods differ. BLA products get 12 years of data exclusivity vs. 5 years for NDA products.
How long does FDA approval take after Phase III? Typically 12-18 months from completing Phase III to approval. This includes NDA preparation (3-6 months), filing review (2 months), and FDA review (6-10 months). If a Complete Response Letter is issued, add another 6-12 months.
Can a drug be sold before full approval? Under accelerated approval, yes. The drug reaches market based on surrogate endpoints, with a requirement to complete confirmatory trials post-approval. If those trials fail, FDA can withdraw approval. Emergency Use Authorization (EUA) is a separate, faster pathway used during public health emergencies.
How much does an NDA submission cost? The PDUFA fee for a new NDA is approximately $4.0 million in 2026. Total development cost for a successful drug (including failed candidates) averages $1-2.6 billion.
What percentage of approved drugs get withdrawn later? About 3-4% of approved drugs are eventually withdrawn from market for safety reasons. Post-market surveillance catches risks that pre-approval trials missed due to limited sample sizes and shorter follow-up periods.
What is a PDUFA date? The FDA's target date to complete its review of an NDA/BLA. Set by the Prescription Drug User Fee Act. Standard review: 10 months from filing. Priority review: 6 months. The FDA usually meets PDUFA dates (>90% on-time in recent years).
What is the difference between Fast Track, Breakthrough, and Priority Review? Fast Track gives more frequent FDA meetings and rolling review. Breakthrough adds intensive guidance and organizational commitment. Priority Review shortens the review clock from 10 to 6 months. Accelerated approval allows approval on surrogate endpoints. A drug can have multiple designations simultaneously.
What happens if the FDA rejects a drug? The FDA issues a Complete Response Letter explaining what additional data or changes are needed. The sponsor can resubmit (triggering a new 6-10 month review), request a hearing, or withdraw the application entirely.
Where can I track drugs currently under FDA review? The FDA publishes PDUFA action dates (target decision dates) for drugs under review. These appear on the FDA website. Industry trackers (BioPharma Catalyst, FDA Calendar) aggregate upcoming dates. ClinicalTrials.gov shows which drugs have completed Phase III.
How does the FDA decide between standard and priority review? Priority review is granted to drugs offering a significant improvement in safety or effectiveness over existing treatments. The sponsor can request it at submission. About 50% of novel drug approvals receive priority review.
Data from FDA CDER annual approval reports, openFDA drugsfda endpoint, and published PDUFA performance metrics. Last verified August 2026.
Want this data programmatically? The MyfitByte API tracks FDA drug approvals, recalls, and safety data. See our FDA recall classes explainer and openFDA API guide for related content.
Published on 2026-07-30 · 13 min read
← Back to all articles